Tekla Capital Management LLC Cellectis S.A. Transaction History

Tekla Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$14.36 - $20.93 $171,673 - $250,218	-11,955 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$15.87 - $31.64 $1.56 Million - $3.11 Million	-98,192 Reduced 89.15%	11,955 $324,000
Q2 2019 Aug 14, 2019	SELL	$14.6 - $20.6 $918,164 - $1.3 Million	-62,888 Reduced 36.34%	110,147 $1.72 Million
Q1 2019 May 14, 2019	SELL	$15.53 - $19.75 $986,077 - $1.25 Million	-63,495 Reduced 26.84%	173,035 $3.17 Million
Q4 2018 Feb 13, 2019	SELL	$15.58 - $28.41 $661,495 - $1.21 Million	-42,458 Reduced 15.22%	236,530 $3.94 Million
Q3 2018 Nov 13, 2018	SELL	$25.99 - $30.6 $1.01 Million - $1.19 Million	-38,962 Reduced 12.25%	278,988 $7.87 Million
Q2 2018 Aug 13, 2018	BUY	$27.78 - $38.53 $963,966 - $1.34 Million	34,700 Added 12.25%	317,950 $9 Million
Q1 2018 May 14, 2018	SELL	$27.78 - $35.19 $750,060 - $950,129	-27,000 Reduced 8.7%	283,250 $8.93 Million
Q2 2017 Aug 14, 2017	BUY	N/A	310,250	310,250 $8.01 Million

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.